Pluri Inc.

    Jurisdiction
    Israel
    LEI
    529900OZKMF7JGZMYM81
    ISIN
    US72942G2030 (PLUR)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    1 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €891.92K
    Gross margin
    46.2%
    EBIT
    -€19.22M
    EBIT margin
    -2,155.1%
    Net income
    -€18.03M
    Net margin
    -2,021.5%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €2.23M +150.5% -€17.34M -3.8%
    €8.79M +293.4% -€12.93M -25.4%
    N/A N/A

    Dividends

    No dividend payouts

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 31K $132.98K -3.1K Sell

    Add to watchlist

    Notifications